Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by MetLife Investment Management LLC

MetLife Investment Management LLC lifted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) by 2.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 48,717 shares of the biopharmaceutical company’s stock after purchasing an additional 1,135 shares during the period. MetLife Investment Management LLC owned about 0.05% of Intra-Cellular Therapies worth $2,267,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in ITCI. US Bancorp DE increased its position in Intra-Cellular Therapies by 93.8% in the 2nd quarter. US Bancorp DE now owns 496 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 240 shares during the period. Assetmark Inc. increased its position in Intra-Cellular Therapies by 410.0% in the 2nd quarter. Assetmark Inc. now owns 510 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 410 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Intra-Cellular Therapies in the 3rd quarter valued at about $41,000. Northern Oak Wealth Management Inc. acquired a new position in Intra-Cellular Therapies in the 2nd quarter valued at about $51,000. Finally, Quantbot Technologies LP purchased a new stake in Intra-Cellular Therapies in the 3rd quarter valued at approximately $55,000. Institutional investors and hedge funds own 86.95% of the company’s stock.

Intra-Cellular Therapies Stock Performance

ITCI opened at $47.32 on Monday. The business’s fifty day moving average is $49.37 and its two-hundred day moving average is $49.69. The company has a market cap of $4.48 billion, a price-to-earnings ratio of -14.25 and a beta of 1.10. Intra-Cellular Therapies, Inc. has a one year low of $42.42 and a one year high of $66.00.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 27,848 shares of the business’s stock in a transaction on Tuesday, February 21st. The stock was sold at an average price of $46.83, for a total transaction of $1,304,121.84. Following the sale, the chief executive officer now directly owns 1,100,309 shares in the company, valued at $51,527,470.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Intra-Cellular Therapies news, CEO Sharon Mates sold 27,848 shares of the business’s stock in a transaction on Tuesday, February 21st. The stock was sold at an average price of $46.83, for a total transaction of $1,304,121.84. Following the sale, the chief executive officer now directly owns 1,100,309 shares in the company, valued at $51,527,470.47. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michael Halstead sold 50,000 shares of the company’s stock in a transaction on Thursday, December 1st. The shares were sold at an average price of $53.73, for a total value of $2,686,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 192,594 shares of company stock worth $9,817,000. 3.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

ITCI has been the subject of several recent analyst reports. Canaccord Genuity Group raised their price target on Intra-Cellular Therapies from $90.00 to $93.00 in a report on Friday, November 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $70.00 price objective on shares of Intra-Cellular Therapies in a report on Friday, February 10th. StockNews.com raised Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a report on Friday, November 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $83.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, February 1st. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Intra-Cellular Therapies has a consensus rating of “Moderate Buy” and a consensus target price of $71.38.

About Intra-Cellular Therapies

(Get Rating)

Intra-Cellular Therapies, Inc operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS.